Booming US Generic Drug Market

Table of Contents

1. Analyst View

2. Global Generic Drugs Market

• 2.1 Market Size & Growth
• 2.2 By Region

3. United States Generic Drugs Market

• 3.1 Most Potential Generic Drugs Market
• 3.2 Market Size & Growth
  • 3.2.1 Pharmaceutical Market
    • 3.2.1.1 By Therapeutic Category
    • 3.2.1.2 By Drugs Category
      • 3.2.1.2.1 Branded Drugs
      • 3.2.1.2.2 Branded Generics
      • 3.2.1.2.3 Unbranded Generics
    • 3.2.1.3 Unbranded Generics witnessing Fastest Growth

4. Regulatory Environment

• 4.1 Drug Efficacy Study Implementation (DESI) Program
• 4.2 Hatch-Waxman Act
• 4.3 Patent Infringement Litigations
• 4.4 Para IV & the 180-day Marketing Exclusivity
• 4.5 FDA Requirements
• 4.6 Generic Initiative for Value & Efficiency (GIVE)

5. Industry Analysis

• 5.1 Driving Forces
  • 5.1.1 Huge Cost Savings
  • 5.1.2 Patent Expiries
  • 5.1.3 Favorable Political Environment
  • 5.1.4 Ageing Population
  • 5.1.5 Large Uninsured Population
  • 5.1.6 Obesity
• 5.2 Opportunities
  • 5.2.1 Patent Expiry of Key Drugs
  • 5.2.2 Biogenerics
  • 5.2.3 Contract Manufacturing
  • 5.2.4 Drugs Packaging
  • 5.2.5 Drugs Delivery
• 5.3 Challenges
  • 5.3.1 Lawsuits
  • 5.3.2 High Entry Barriers
  • 5.3.3 Price Erosion & Depleting Margins
  • 5.3.4 Authorized Generics

6. Future Outlook (2007-2011)

• 6.1 Driving & Restraining Forces
• 6.2 Sales

7. Competitive Landscape

• 7.1 Market Share of Key Players
• 7.2 Profile of Key Players
  • 7.2.1 Teva Pharmaceutical Industries Limited
  • 7.2.2 Watson Pharmaceuticals, Inc.
  • 7.2.3 Mylan Laboratories Inc.
  • 7.2.4 Sandoz Inc.
  • 7.2.5 Actavis Group hf

8. Supporting Databases

• 8.1 Macroeconomic Indicators
• 8.2 Population
• 8.3 Demographics
• 8.4 Healthcare Expenditure
• 8.5 Healthcare Infrastructure
• 8.6 Major Causes of Mortality

List of Figures:

• Figure 2-1: Global - Generic Drugs Market (in Billion US$), 2006 & 2010F
• Figure 2-2: Global - Pharmaceutical Market (in Billion US$), 1999-2006
• Figure 2-3: Global - Unbranded Generic Drugs Market (in Billion US$), 2001-2006 & 2010F
• Figure 2-4: Global - Share of Unbranded & Branded Generics in Generic Drugs Market (%), 2006 & 2010F
• Figure 2-5: Global - Breakup of Unbranded Generic Drugs Market by Region (%), 2006
• Figure 3-1: Global - Top Unbranded Generic Drugs Market (in Billion US$), 2006
• Figure 3-2: Global - Top Pharmaceutical Markets (in Billion US$), 2006
• Figure 3-3: Global - Per Capita Drugs Consumption of Top Pharmaceutical Markets (in US$), 2006
• Figure 3-4: US - Number of Prescriptions for Pharmaceutical Market (in Billion), 2004-2006
• Figure 3-5: US - Pharmaceutical Market (in Billion US$), 2002-2006
• Figure 3-6: US - Prescriptions Breakup for Pharmaceutical Market by Drug Category (%), 2006
• Figure 3-7: US - Sales Breakup of Pharmaceutical Market by Drug Category (%), 2006
• Figure 3-8: US - Share of Prescriptions for Branded Drugs in Pharmaceutical Prescriptions (%), 2002-2006
• Figure 3-9: US - Number of Prescriptions for Branded Drugs (in Billion), 2005 & 2006
• Figure 3-10: US - Share of Branded Drugs Sales in Pharmaceutical Market (%), 2002-2006
• Figure 3-11: US - Branded Drugs Market (in Billion US$), 2002-2006
• Figure 3-12: US - Share of Prescriptions for Branded Generic Drugs in Pharmaceutical Prescriptions (%), 2002-2006
• Figure 3-13: US - Number of Prescriptions for Branded Generic Drugs (in Billion), 2005 & 2006
• Figure 3-14: US - Share of Branded Generic Drugs Sales in Pharmaceutical Market (%), 2002-2006
• Figure 3-15: US - Branded Generic Drugs Market (in Billion US$), 2002-2006
• Figure 3-16: US - Share of Prescriptions for Unbranded Generic Drugs in Pharmaceutical Prescriptions (%), 2002-2006
• Figure 3-17: US - Number of Prescriptions for Unbranded Generic Drugs (in Billion), 2005 & 2006
• Figure 3-18: US - Share of Unbranded Generic Drugs Sales in Pharmaceutical Market (%), 2002-2006
• Figure 3-19: US - Unbranded Generic Drugs Market (in Billion US$), 2002-2006
• Figure 3-20: US - Breakup of Unbranded Generic Drugs by Formulation Type (%), 2005
• Figure 3-21: US - Sales Growth of Various Pharmaceutical Sectors (%), 2003-2006
• Figure 3-22: US - Share of Branded, Branded Generics & Unbranded Generics in Growth of Pharmaceutical Market (%), 2006
• Figure 4-1: US - Generic Drugs Approval Process
• Figure 4-2: US - Median Approval Time for ANDA Originals (in Months), 2000-2006
• Figure 5-1: US - Product Development Time for Generic & Branded Pharmaceuticals (in Years)
• Figure 5-2: US - Average Retail Price of Branded & Generic Drugs (in US$), 2006
• Figure 5-3: US - Price Comparison of Various Branded & Generic Blood Pressure Drugs (in US$), 2004
• Figure 5-4: US - Average Copayments for Generic Drugs, Preferred Branded Drugs & Non-preferred Branded Drugs (in US$), 2000 & 2004
• Figure 5-5: US - Sales Value of Drugs Loosing Patent Protection (in Billion US$), 2003-2006
• Figure 5-6: US - Comparison of Receipts & Approval of ANDA Applications (in Numbers), 2000-2006
• Figure 5-7: US - Share of State & Other Financing in Pharmaceutical Market (%), 2006
• Figure 5-8: US - Number of Medicare Beneficiaries (in Million), 1970 to 2030F
• Figure 5-9: US - Savings for Medicare from Drugs going Generic (in Billion US$), 2006-2010F
• Figure 5-10: US - Population of Age above 65 Years (in Million), 2001-2006
• Figure 5-11: US - Relative Per Capita Spending on Drugs by Age Group (%)
• Figure 5-12: US - Number of Uninsured People (in Million), 2001-2006E
• Figure 5-13: US - Obese* Population in Age Group 20-74 (%), 1960-1962 to 1999-2002**
• Figure 5-14: US - Relative Medication Cost due to Obesity, Smoking & Overweight (%)
• Figure 5-15: US - Forecast for Breakup of Biogenerics Market by Drugs Type (%), 2016
• Figure 5-16: Global - Contract Manufacturing Market (in Billion US$), 2001, 2006E & 2010F
• Figure 5-17: US - Relationship between Generic Drugs Price & Number of Generic Competitors (%)
• Figure 6-1: US - Population of Age above 65 Years (in Million), 2007-2011F
• Figure 6-2: US - Forecast for Number of Uninsured People (in Million), 2007-2011
• Figure 6-3: US - Forecast for Pharmaceutical Market (in Billion US$), 2007-2011
• Figure 6-4: US - Forecast for Branded Drugs Market (in Billion US$), 2007-2011
• Figure 6-5: US - Forecast for Branded Generic Drugs Market (in Billion US$), 2007-2011
• Figure 6-6: US - Forecast for Unbranded Generic Drugs Market (in Billion US$), 2007-2011
• Figure 6-7: US - Forecast for Penetration of Branded, Branded Generics & Unbranded Generics (%), 2007-2011
• Figure 6-8: US - Forecast for Share of Branded, Branded Generics & Unbranded Generics in Growth of Pharmaceutical Market (%), 2006 to 2011
• Figure 8-1: US - Nominal GDP (in Trillion US$), 2001-2006
• Figure 8-2: US - Nominal GDP (in Trillion US$), 2007-2011F
• Figure 8-3: US - Consumer Price Index (%), 2001-2006
• Figure 8-4: US - Consumer Price Index (%), 2007-2011F
• Figure 8-5: US - Foreign Direct Investment (in Billion US$), 2005 & 2006
• Figure 8-6: US - Population (in Million), 2001-2006
• Figure 8-7: US - Population (in Million), 2007-2011F
• Figure 8-8: US - Life Expectancy (in Years), 2001-2006E
• Figure 8-9: US - Life Expectancy (in Years), 2007-2011F
• Figure 8-10: US - Population Breakup by Age Group (%), 2001-2006
• Figure 8-11: US - Population Breakup by Age Group (%), 2007-2011F
• Figure 8-12: US - Healthcare Spending (in US$ per Head), 2001-2006E
• Figure 8-13: US - Healthcare Spending (in US$ per Head), 2007-2011F
• Figure 8-14: US - Breakup of Healthcare Payments by Source (%), 2005
• Figure 8-15: US - Number of Doctors (per ‘000 Population), 2001-2006E
• Figure 8-16: US - Number of Doctors (per ‘000 Population), 2007-2011F
• Figure 8-17: US - Number of Hospital Beds (per ‘000 Population), 2001-2006E
• Figure 8-18: US - Number of Hospital Beds (per ‘000 Population), 2007-2011F
• Figure 8-19: US - Breakup of Leading Causes of Death (%), 2005
• Figure 8-20: US - Number of Deaths due to Leading Causes, 2005
• Figure 8-21: US - Forecast for Breakup of Leading Causes of Death (%), 2030

List of Tables:

• Table 3-1: US - Retail Pharmaceutical Market by Therapeutic Category (in Million US$), 2006
• Table 5-1: US - Actual & Potential Cost Savings from Using Generic Drugs by Therapy Area (in Billion US$), 2005
• Table 5-2: US - Estimated & Potential Cost Savings from Using Generic Drugs by Therapy Area (in Billion US$), 2006
• Table 5-3: US - Blockbuster Drugs Expected to Lose Exclusivity (2007-2009)
• Table 5-4: US - Patent Expiry Dates for Biopharmaceuticals
• Table 7-1: US - Sales* of Top 10 Players in Generic Drugs Market (in Million US$), 2005
• Table 7-2: US - Number of Prescriptions* of Top 10 Players in Generic Drugs Market (in Million), 2005
• Table 7-3: US - Sales** of Top 10 Players in Generic Drugs Market (in Million US$), 2007*
• Table 7-4: US - Number of Prescriptions** of Top 10 Players in Generic Drugs Market (in Million), 2007*
• Table 7-5: Teva Pharmaceutical Industries Limited - Key Financials (in Million US$), 2004-2006
• Table 7-6: Watson Pharmaceuticals, Inc. - Key Financials (in Million US$), 2004-2006
• Table 7-7: Sandoz Inc. - Key Financials (in Million US$), 2005 & 2006
• Table 7-8: Actavis Group hf - Key Financials (in Million Euro), 2004-2006